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A B S T R A C TBackground: Cardiovascular disease (CVD) is a leading cause of
hospitalizations, death, and health care costs. Although studies have
shown that modifying CVD risk factors at the patient level improves
patient prognosis, the effect of community-wide interventions at the
population level has been uncertain. Objective: To evaluate the
resource use and cost consequences of a community-wide Cardio-
vascular Health Awareness Program (CHAP). Methods: Thirty-nine
medium-sized communities in Ontario, Canada, participated in a
community cluster randomized controlled trial stratified by popula-
tion size and geographic location. All community-dwelling elderly
residents (465 years) in each community were included. Family
physicians, pharmacists, community nurses, local organizations,
and volunteers in the intervention communities implemented the
program. Rates and costs of CVD hospitalizations, all hospitalizations,
emergency department visits, physician visits, and prescription med-
ication use in the year before and after the intervention were
compared for the 19 control and 20 CHAP communities by usingee front matter Copyright & 2013, International S
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ondence to: Ron Goeree, Programs for the Asses
n, 25 Main Street West, Suite 2000, Hamilton, Ontprovince-wide linked administrative databases. The cost of imple-
menting and administrating CHAP in each community was combined
with total community health care cost to determine the net cost
effect. Results: CHAP was associated with a reduction in CVD hospi-
talization costs. There were no differences in utilization rates or costs
for overall hospitalizations, in visits to emergency rooms, physicians,
or specialists, or in the use of prescription medications. Results were
robust over a range of cost assumptions. Conclusions: A community-
wide CVD awareness program can be implemented and can reduce
CVD-related hospitalization costs at the level of the community
without a corresponding increase in overall health care costs.
Keywords: Cardiovascular, Cluster randomized controlled trial,
Community-wide intervention, Cost analysi, Cost consequence
analysis, Economic evaluation.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Heart disease and stroke are among the most common, costly,
and preventable conditions responsible for significant disability,
death, and cost to health care systems and society. Approxi-
mately 5% of the Canadian population has heart disease [1–3],
and together with stroke, cardiovascular disease (CVD) is respon-
sible for 30% of Canadian deaths [4,5], 3 million or 17% of all
hospitalizations [1–3], and more than $20 billion in costs each
year [1,6,7]. Although the overall rate of hospitalizations for CVD
has been decreasing over the past two decades [3], the actual
number of hospitalizations and deaths is projected to increase inthe future because of the aging population and an increase in the
prevalence of CVD risk factors among children and young adults.
This confluence of factors was described in a recent report by the
Heart and Stroke Foundation of Canada as ‘‘A Perfect Storm’’ that
will continue to increase the burden of CVD [8].
Among Canadians who do not already have overt CVD, many
run a high risk of developing it. Approximately 80% of the
population has at least one modifiable risk factor for CVD, and
10% have three or more risk factors [5]. Among the traditional
CVD risk factors (i.e., smoking, physical inactivity, obesity, high
blood pressure, and diabetes), the prevalence of high blood
pressure rose from 11.6% to 14.4% over the past few years alone,ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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sure whereas only 66% have it treated and under control [9]. The
underdetection and undertreatment of hypertension and other
risk factors for CVD leads to large social and economic burdens in
terms of hospitalizations, other health care utilization, excess
mortality, and potential years of life lost [10]. Therefore, decreas-
ing these risk factors at the population level can have a large
effect on reducing the burden of CVD.
CVD is largely preventable and manageable through lifestyle
interventions and pharmacological therapies [11]. In 2003, how-
ever, the Heart and Stroke Foundation of Canada reported that
up to 60% of the Canadians were ‘‘seriously misinformed’’ with
respect to their knowledge of the risk factors and warning
symptoms of heart disease and stroke. It was recommended
that patient health literacy strategies should emphasize aware-
ness of risk factors, especially hypertension, and the focus
should be on primary and secondary prevention [12]. A number
of mass media campaigns have targeted increased awareness
about these modifiable risk factors and how they can be better
identified and managed. In addition, there has been a greater
emphasis on encouraging family physicians to spend more time
with their patients to identify and appropriately treat these risk
factors. Although there have been noticeable advances in the
identification and treatment of CVD using these approaches,
there remain significant barriers in terms of patient denial,
underdiagnosis, misdiagnosis due to multiple health conditions,
suboptimal treatment, and patient nonadherence to lifestyle
modifications or recommended treatment. There is a clear
need for innovative approaches to help identify and emphasize
the importance of preventing and appropriately treating CVD
risk factors.
An alternative approach to individual patient intervention is
to manage patients through community-wide CVD prevention
and surveillance programs. An example of such a program is the
Chronic Care Model described by Wagner et al [13], which has
elements of improved clinical information, decision support,
delivery systems, self-management support, and community/
organizational leadership. Community empowerment, including
participation and linking with other people and organizations,
can lead to improvement in health outcomes of community
residents [14]. In a recent systematic review, Pennant et al. [15]
identified 36 controlled and observational studies of community
programs for the prevention of CVD. A large number of these
studies reported a positive trend in CVD risk score, but only a few
reported positive changes in CVD/mortality rates, and in all but
one, the change was nonsignificant. These negative results could
possibly be due to biases that arise because these studies were
not randomized controlled trials (RCTs). Negative results could
also be due to the nature of the interventions evaluated, because
small-scale or short time-line interventions may not result in a
significant and sustained effect for a community as a whole.
Given that these programs have failed to show benefits on major
health outcomes [15], it is not surprising that no economic
evaluations of community-wide CVD interventions have been
conducted.
Presented here is an economic evaluation of a recently re-
ported trial [11] assessing the effectiveness of a community-wide
Cardiovascular Health Awareness Program (CHAP) [10,11,16–18].
Established 10 years ago, CHAP was designed to improve cardi-
ovascular health at a population level using a community-level
intervention aimed at shifting the population CVD risk profile.
CHAP was developed and refined through several pilot studies,
scientific trials, and community-wide demonstration projects
in Ontario and Alberta, Canada, and then was expanded
and rigorously evaluated in a large multicommunity trial. The
specific objective of this study was to compare the resource
use and cost consequences in communities with a structuredcommunity-wide CHAP versus communities without such a
program (i.e., usual care).Methods
Overview of the CHAP Community Trial Study Design
A detailed description of the CHAP intervention, community-
wide study design, and outcomes was reported elsewhere
[10,16–18]. In brief, a cluster RCT was conducted in 39 cities/
towns across Ontario, with populations between 10,000 and
60,000 inhabitants and these communities stratified by geo-
graphic location and population size of residents 65 years
and older. Communities within each stratum were randomly
allocated to either the intervention (n ¼ 20) arm or the control
(n ¼ 19) arm of the study. The total population of the study
communities at the start of the intervention period was 973,246,
with 140,642 community-dwelling residents 65 years and older.
Residents who resided in long-term care facilities were excluded
from the trial, because they had no opportunity to participate in
CHAP sessions [10]. Although residents in long-term care facil-
ities could benefit from community-wide informational sessions
and other interventions such as those offered through CHAP,
our pilot work revealed that participation in CHAP for residents
in long-term care facilities would be problematic and therefore
the effect of CHAP would be minimal for these residents.
For this reason, our study targeted community-dwelling elderly
residents only.Interventions Compared
In both study communities, residents received the usual health
promotion and health care services available to all residents
under Ontario’s publicly financed universal health insurance sys-
tem [11]. Information on other health promotion activities during
the study period was collected at the beginning, during, and at
the end of the study.
In addition to usual health promotion and health care ser-
vices, the elderly residents in the intervention communities were
exposed to CHAP. CHAP is a multipronged prevention program
that mobilized and coordinated health professionals and
community-based organizations to better identify and manage
heart disease and stroke risk factors. Through a number of
different strategies designed to reach out to residents during
the autumn of 2006 [10,11,16,18], elderly residents in the inter-
vention communities were invited to attend blood pressure
and CVD risk-factor assessment and education sessions held
during a 10-week period operated by trained volunteers in local
pharmacies concurrently in all 20 intervention communities.
With participants’ consent, summary CVD risk profile reports
were sent to their family physician and regular pharmacist. In
addition, each participant received a copy of the report, along
with cardiovascular health education materials and a list of local
resources supporting lifestyle changes. Participants were referred
to community health nurses and pharmacists as needed for
follow-up and drug-related consultations. At the end of the
10-week program, all session results were forwarded to family
physicians in the form of reports that rank ordered their patients
by systolic blood pressure and diagnostic/treatment status. Six
months later, aggregate-level comparative feedback, along with
individual patient data, was sent to family physicians, again
showing blood pressure control of patients from their practice
who participated in CHAP compared with patients of other family
physicians in their own community and across all 20 intervention
communities [10,11].
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The primary outcome measure of the overall study was the mean
annual number of hospital admissions for acute myocardial
infarction (MI), congestive heart failure (CHF), and stroke among
trial elderly residents in intervention and control communities.
Secondary outcome measures included mortality among patients
hospitalized for CVD and coronary artery disease, all-cause
mortality, hospitalizations for stroke and coronary artery disease,
and initiation of antihypertensive drug therapy [10,11]. The
assessment of CHAP outcomes was based on the retrospective
analysis of routinely collected, population-based administrative
health data and was focused on the relative change in the mean
primary and secondary outcome event rates at the community
level in the year before (September 1, 2005, to August 31, 2006:
‘‘preintervention’’) compared with the year after (September 1,
2007, to August 31, 2008: ‘‘postintervention’’) the implementation
of CHAP. Health data collected for the preintervention period
were used to compute baseline outcome event rates at the
community level, which enabled adjustment for any imbalances
at baseline not accounted for through community randomization
[10]. Because this was an assessment at the level of the entire
community longitudinally over a year and at two time periods (i.e.,
pre- and postintervention), the number of patients in each com-
munity was different at the beginning and at the end of each time
period and during each time period due to mortality, migration in
and out of communities, and aging of residents in the community.
Therefore, although mean rates of hospitalization and other health
care use were calculated on the basis of the number of elderly
residents in the communities, the rates over time were not based
on the same elderly residents in the communities at each time
point. Because of this, CHAP was designed and approved by
research ethics boards to be conducted at the level of community
using aggregated community data. Individual patient consent,
required for linking of patient administrative data, was not obtained
for this study, and only aggregated data were used in the analysis.
Economic Appraisal—Resource Use and Cost Consequences
The economic appraisal comprised two components: a comparison
of health care resource use across the intervention and control
communities and a comparison of the cost consequences of health
care resource use across the intervention and control communities.
For the health care utilization analysis, the rates of health care
resource utilization over the preintervention and the postinterven-
tion periods were obtained for senior residents in both interven-
tion and control communities by using linked administrative
health data housed at the Institute for Clinical and Evaluative
Sciences [19]. Residents 65 years and older in each community
were identified through birth dates and place of residence (i.e.,
community or long-term care facility), and then the unique patient
identifier for community-dwelling residents was used to obtain all
health care resource use over the 1-year follow-up period for the
entire cohort of patients. Community-wide information on hospi-
talizations, hospital emergency department visits, family physi-
cian visits, specialist physician visits, and prescription drug use for
all community-dwelling elderly residents in each community were
compared for the pre- and postintervention periods. Rates of use
for each health care category (e.g., hospitalizations and prescrip-
tion drug claims) were computed by dividing total community use
by the number of community-dwelling residents in the commu-
nity. These rates were compared across control and intervention
communities in the postintervention period after controlling
for resource use in the preintervention period (see the Statistical
Analyses subsection). The number of elderly residents in the
communities was different across the time periods owing
to mortality, migration in and out of the communities, and aging
of the population in the communities over time. As such, theeconomic analysis was conducted at the level of the community
and not at the level of individual patients. Data sources included
the hospital discharge abstract database of the Canadian Institute
for Health Information [20], the physician service claim database
of the Ontario Health Insurance Plan [21], and the prescription
drug claim database of the Ontario Drug Benefit Program [22].
The cost consequence analysis comprised two components:
the incremental cost of CHAP for each intervention community
and the health care cost of hospitalizations, emergency depart-
ment visits, family doctor and specialist visits, and prescription
drug claims for all community-dwelling seniors in each commu-
nity for the year after the intervention period. In terms of CHAP
intervention costs, considerable administration, organizational,
and logistical issues needed to be completed before CHAP could
be implemented in each community. As such, CHAP preimple-
mentation and actual implementation occurred over a 20-month
period from January 2006 to August 2007. Costs incurred during
this time period included development and planning costs, hiring
and training costs, setup costs, and costs of implementing CHAP.
The total cost of CHAP implementation directly attributable to
each of the intervention communities was based on recorded
expenditures for staff salaries, program advertising, equipment
(e.g., blood pressure devices, pagers, and cell phones), materials
(e.g., tables and chairs), travel, meetings, and office supplies.
Because of considerable variability in, and inherent difficulties in,
estimating specific information around administration resources
provided ‘‘in kind’’ by intervention communities, ‘‘in-kind’’ re-
sources were not included in the base-case cost analysis and
various scenarios were considered in sensitivity analyses. In
addition to pre- and implementation costs directly incurred by
each community, there were significant CHAP costs incurred by
two regional CHAP coordinators and by the central CHAP team
administration [11]. The cost of centralized CHAP services
included data management services (Clinforma) [23], the cost of
personnel, operating costs, and the cost of transportation, equip-
ment, materials, and supplies. The allocation of CHAP central
costs to each intervention community was based on the propor-
tion of eligible residents in each community. Alternative allocation
bases for CHAP central costs were tested in sensitivity analyses.
Costing for health care resource utilization at the community
level (i.e., hospitalizations, emergency department visits, family
physician and specialist physician visits, and prescription drug
claims) for community-dwelling seniors for the year after the
intervention period was based on resources reported in the
province-wide linked administrative databases multiplied by unit
costs of each resource consumed. Unit prices/costs were obtained
from various sources. The cost of hospitalizations was based on
the case-mix group for each admission multiplied by the corre-
sponding resource intensity weight for the admitting hospital
and the case-mix group [24]. The cost of emergency department
visits was based on average costs from the Ontario Case Costing
Initiative [25], and the cost of prescription drugs was the amount
paid by the provincial government (including applicable dispen-
sing fees) recorded in the Ontario Drug Benefit Database [22].
Finally, physician service payments were obtained from the
Claims History Database of the Ontario Health Insurance Plan
[21]. A sample of unit costs is presented in Table 1.
All costs are expressed in 2010 Canadian dollars, and because
of the short time horizon of the cost analysis (i.e., 1 year),
discounting of costs in future years was not required. The
perspective of the cost analysis was from the Ontario Ministry
of Health and Long-Term Care.
Sensitivity Analyses
To test the robustness of the analysis to alternative costing
assumptions, a number of sensitivity analyses were conducted.
Table 1 – Selected unit costs assigned for costing the administrative databases (in 2010 Canadian dollars).
Resource item Unit cost (2010 CAN$) Source
Hospital admission (average cost for typical case minus physician services)
CMG 194: Myocardial infarction (without cardiac catheter) 7656.00 CIHI
CMG 196: Heart failure (without cardiac catheter) 6633.00 CIHI
CMG 028: Unspecified stroke 6947.00 CIHI
Visits to hospital emergency departments (average cost minus physician services) 252.94 OMOHLTC
Family physician consultation 62.65 OHIP SOB
Specialist (internal medicine) consultation 143.40 OHIP SOB
Common prescription medications (drug benefit price)
Ramipril, 10 mg capsule, generic 0.48 ODB Formulary
Quinapril, 40 mg tablet, brand 0.85 ODB Formulary
Hydrochlorothiazide, 50 mg tablet, generic 0.05 ODB Formulary
CIHI, Canadian Institute for Health Information; CMG, case-mix group; ODB, Ontario Drug Benefit Plan; OHIP SOB, Ontario Health Insurance
Plan Schedule of Benefits; OMOHLTC, Ontario Ministry of Health and Long-Term Care.
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on the composite of admissions associated with a most respon-
sible diagnosis of acute MI, CHF, or stroke (i.e., the CHAP primary
outcome measure) was conducted. We also explored alternative
assumptions regarding the allocation of CHAP central adminis-
tration costs to intervention communities. We examined two
scenarios: no central administration costs allocated to interven-
tion communities and an equal allocation to each community
(i.e., total CHAP central administration cost divided by 20).
Intervention communities provided ‘‘in-kind’’ administration
resources (e.g., volunteer time, office space, equipment, and
furniture). Because these resources were inconsistently docu-
mented by the participating communities, however, we assessed
the effect of incorporating a series of fixed ‘‘in-kind’’ contribu-
tions ($5,000, $10,000, and $15,000, respectively) from each inter-
vention community. Finally, given that there was a recent change
in generic drug pricing in the province of Ontario that resulted in
a significant decrease in the cost of generic drug prices, which
would not be reflected in the drug prices observed during our
study period, we examined the effect of reducing drug prices
across the board by 25%.Statistical Analyses
For the analysis of community health resource utilization rates
and costs, we used ordinary least squares (OLS) regression
models for each resource use category (e.g., hospitalizations,
physician visits, and prescription drugs) and for each cost
category (e.g., hospital costs, physician visit costs, and prescrip-
tion medication costs). Because data were obtained for the level
of the community and the number of patients in each commu-
nity was different over time due to mortality, migration in and
out of the communities, and aging of residents in the commu-
nities, the unit of analysis was the community. The dependent
variable was the postintervention count (i.e., number of counts in
each resource use category or cost in each subcategory), and we
regressed this on the intervention indicator variable (i.e., one for
intervention and zero for control communities) and the preinter-
vention count. The mean difference in utilization rates (inter-
vention vs. control) was calculated for the resource use analyses
and the mean difference in costs for the cost analyses. OLS
assumptions were tested with the following two methods: First,
the studentized and jackknife residuals were plotted in a uni-
variate fashion and the distribution was normality tested byusing the Shapiro-Wilk test. Second, homoscedasticity was gra-
phically evaluated by plotting the residuals against the predicted
values of the dependent variable. SAS version 9.1.12 was used for
all analyses (SAS Institute, Cary, NC).Results
Primary Findings from the Overall Study
As previously reported, the control and intervention commu-
nities were well balanced and CHAP was successfully implemen-
ted in all 20 randomly selected communities [10,16,17]. The main
clinical finding was a statistically significant and clinically
important 9% relative reduction in the rate of hospital admis-
sions for acute MI, CHF, and stroke for the entire population of
residents 65 years and older during the year after the implemen-
tation of CHAP, compared with control communities [11].
Economic Appraisal—Resource Use and Cost Consequences
The results comparing the rates of CHAP resource utilization in
the intervention versus control communities by resource use
category are listed in Table 2. As shown in Table 2, CHAP was
associated with a lower absolute rate of hospitalizations for the
composite outcome of acute MI, CHF, and stroke (2.90 mean
hospitalizations per 1000 people; 95% confidence interval
[CI] 5.98 to 0.18; P ¼ 0.064). The rate of hospital admission was
the same for both groups in the postintervention period (i.e., 243
per 1000), and even after adjusting for baseline imbalances, the
difference in the mean rate of total hospitalizations was similar
for both communities (8.46; 95% CI 19.79 to 2.94; P ¼ 0.141).
Similarly, the difference in the mean rate of hospital emergency
department visits (4.71; 95% CI 37.93 to 47.35; P ¼ 0.824), family
physician visits (95.37; 95% CI 353.80 to 163.06; P ¼ 0.824),
specialist visits (15.10; 95% CI 120.25 to 150.45; P ¼ 0.822), and
prescription medication use (263.07; 95% CI 215.36 to 741.50; P ¼
0.272) was similar in both communities.
Community-based CHAP intervention costs ranged from as
low as $11,976 to as high as $57,113, depending on the commu-
nity size, internal volunteer support, and the availability of ‘‘in-
kind’’ infrastructure support. Across all intervention commu-
nities, the total community-based cost was $609,874 or an
average of $30,494 per community. In addition, CHAP central
costs amounted to $804,304 or an average of $40,215 per
Table 2 – Comparison of utilization rates (mean per 1000 patients) for selected resources, by study arm and study time period.
Resource item Preintervention period
(September 1, 2005,
to August 21, 2006)
Postintervention period
(September 1, 2007,
to August 31, 2008)
CHAP minus control
utilization difference,†
(95% CI); P value
CHAP
(n ¼ 67,874)
Control
(n ¼ 72,768)
CHAP
(n ¼ 69,942)
Control
(n ¼ 75,499)
CHAP hospitalizationsz 30 29 28 30 2.90 (5.98, 0.18); 0.064
All hospitalizations 265 254 243 243 8.46 (19.79, 2.94); 0.141
Visits to hospital
emergency departments
778 754 804 774 4.71 (37.93, 47.35); 0.824
Family physician claims 6058 6421 5496 5894 95.37 (353.80, 163.06); 0.459
Specialist claims 2820 2901 2865 2918 15.10 (120.25, 150.45); 0.822
Prescription drug claims 6385 6454 7621 7438 263.07 (215.36, 741.50); 0.272
CHAP, Cardiovascular Health Awareness Program; OHIP, Ontario Health Insurance Plan.
* Postintervention period rates adjusted for preintervention rates.
† All regression models satisfied ordinary least squares assumption testing (Po 0.01), with the exception of specialist visits and the number of
prescription drug claims.
z Composite of admissions associated with a most responsible diagnosis of acute myocardial infarction, congestive heart failure, or stroke.
Table 3 – Comparison of mean annual health care and interventions costs per resident, by study arm and study time period
(in 2010 Canadian dollars).
Resource item Preintervention period
(September 1, 2005,
to August 21, 2006)
Postintervention period
(September 1, 2007,
to August 31, 2008)
CHAP minus control
cost difference
(95% CI); P value
CHAP
(n ¼ 67,874)
Control
(n ¼ 72,768)
CHAP†
(n ¼ 69,942)
Control
(n ¼ 75,499)
CHAP hospitalizations only† 282 269 269 303 39.72 (77.80, 1.64); 0.041
All hospitalizations 2164 2110 2160 2129 18.67 (157.09, 119.76); 0.786
Visits to hospital emergency
departments
259 255 265 265 4.27 (16.10, 7.57); 0.470
Family physician visits 191 200 174 184 1.93 (10.16, 6.31); 0.638
Specialist visits 137 141 141 143 1.45 (3.62, 6.51); 0.566
Prescription drug claims 1382 1422 1437 1474 0.42 (30.87, 31.70); 0.979
Intervention costs — — 20.20z — 20.20§; n/a
Total health care and
intervention costs
4132 4128 4198 4196 1.69 (155.76, 152.39); 0.982
CHAP, Cardiovascular Health Awareness Program; CI, confidence interval; n/a, not applicable/available.
* Postintervention period costs adjusted for preintervention costs.
† Composite of admissions associated with a most responsible diagnosis of acute myocardial infarction, congestive heart failure, or stroke.
z Intervention costs (for base case): $1,414,178/69,942 or $20.20 per senior resident.
§ Average intervention cost of $20.20 per resident applied to all residents in intervention communities; therefore, no variability for confidence
intervals.
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based CHAP intervention and CHAP central cost was $1,414,178
(excluding in-kind contributions). This equated to approximately
$71,000 per community or $20.20 per elderly resident.
As shown in Table 3, the average health care cost per elderly
resident in the year before the intervention was approximately
$4100, with 50% of this total due to hospitalizations, 15% due to
emergency department and doctor visits, and 35% due to med-
ication drug use. The additional cost of the CHAP intervention
(i.e., $20.20 per resident) was offset by slightly lower health
care costs in the intervention communities such that the total
cost in the year after the intervention was equal in both groups
at approximately $4200 per elderly resident (mean cost dif-
ference $1.69; 95% CI $156.76 to $152.39; P ¼ 0.982). The
distribution of total costs by resource use category remainedthe same in the pre- and postintervention periods. With the
exception of hospital costs for the composite outcome of
acute MI, CHF, and stroke (mean cost difference $39.72; 95%
CI $77.80 to $1.64; P ¼ 0.041), the difference in costs was not
statistically significantly different for total hospitalizations or any
of the other cost subcategories.
All 14 regression models held to the OLS assumptions except
two: utilization of specialists and the number of prescription drug
claims. Residuals for these two outcomes were not normally
distributed (P o 0.01).
Sensitivity Analyses
Given in Table 4 are the sensitivity analyses under different
costing assumptions: 1) which hospitalization costs to include
Table 4 – Sensitivity analyses on key cost assumptions (in 2010 Canadian dollars).
Cost variable Base case assumption Assumption(s) for
sensitivity analysis
Cost difference (95% CI);
P value
Hospitalization included in cost analysis All hospitalizations CHAP hospitalizations† 29.15 (81.49, 23.18); 0.266
CHAP central costs Included in analysis Excluded from analysis 13.18 (167.24, 140.87); 0.863
Allocation basis of fixed CHAP central
costs to intervention communities
Proportion of eligible
residents in each
community
Equal allocation to all
20 communities
1.64 (152.15, 155.43); 0.983
Administration resources provided ‘‘in
kind’’ by intervention communities
Not included (1) $5,000 to each
community
0.16 (153.88, 154.20); 0.998
(2) $10,000 to each
community
2.00 (152.00, 156.00); 0.979
(3) $15,000 to each
community
3.84 (150.13, 157.81); 0.960
Prescription drug costs As incurred during
observation periods
25% reduction in drug
costs
1.70 (153.31, 149.92); 0.982
CHAP, Cardiovascular Health Awareness Program.
* Postintervention period costs adjusted for preintervention costs.
† Composite of admissions associated with a most responsible diagnosis of acute myocardial infarction, congestive heart failure, or stroke.
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costs, 3) assumptions regarding the estimated value of in-kind
contributions from the intervention communities, and 4) results
assuming a general lowering of prescription medication costs in
the province as occurred in the year after the completion of the
study. These results show that the overall cost findings are
somewhat sensitive to whether the total health care cost esti-
mate incorporates the subset of hospitalizations included in the
primary outcome measure (acute MI, CHF, and stroke; $29.15
[$81.49, $23.18]; P ¼ 0.266) as opposed to all hospitalizations.
The inclusion or allocation of CHAP central costs, the estimate of
in-kind contribution, and the use of lower drug costs, however,
did not have a substantial effect on the cost differences.Discussion
As CVD is largely preventable and manageable through lifestyle
modifications and pharmacological therapies, programs aimed at
identifying and modifying patient risk factors can have a sub-
stantial effect on patient outcomes and costs to the health care
system. Nevertheless, a significant proportion of patients lack
knowledge about CVD risk factors in general and more specifi-
cally about the early warning signs of CVD. In addition, a number
of patients are underdiagnosed for CVD and misdiagnosed owing
to having multiple chronic diseases and physicians are often
reluctant to initiate aggressive pharmacological treatments. As a
result, individual patient, clinician, clinic, and community bar-
riers exist for initiatives aimed at CVD prevention and manage-
ment. Physician-based programs such as monitoring of patient
risk factors, increased education of patients about CVD risk
factors, initiatives targeted toward increased patient compliance
with therapy, or changes in lifestyle behavior are resource
intensive and as a result have had limited uptake.
Community-wide CVD education and awareness programs
such as CHAP have the appeal of potentially reaching a wide
audience, and because of physician reluctance to initiate aggres-
sive therapy, limited time spent with patients, misdiagnoses, and
patient denial, these programs can potentially be more effective
than individual-level strategies. This evaluation demonstrated
that a CHAP-like community-wide CVD awareness program can
be successfully implemented and can reduce CVD-related hospi-
talization costs at the level of the community without increasing
overall health care costs. Nevertheless, despite the success ofCHAP, previous community-wide CVD programs have produced
mixed results. Controlled and observational studies identified by
Pennant et al. [15] in a recent systematic review were limited to
assessing changes in CVD risk scores and not actual CVD events
or hospitalization rates. Across all studies, the net reduction in
10-year CVD risk was 9.08%, which is similar to the 9% relative
risk reduction of CVD hospitalizations found for CHAP. Only a
handful of these community programs examined changes in
CVD/mortality rates and most of these reported a positive, but
nonsignificant, treatment effect. The difference in the results
from CHAP and these previously conducted community-wide
CVD programs may be due to study design. For example, non-
RCTs can be influenced by confounding factors that can poten-
tially bias the analysis. Similarly, interventions done on a small-
scale/scope or for a short period of time may not be sufficient to
result in a significant and sustained effect for a community as
a whole.
There are a number of strengths of our study. First, CHAP is an
exemplar program of the Chronic Care Model [13] as it comprises
all the models’ essential elements including improved clinical
information systems, decision support, improved delivery system
design, self-management support, and community and organiza-
tional leadership. Although the findings from this study apply
specifically to CHAP in the communities evaluated, we believe
that the intervention components of CHAP can be implemented
elsewhere and therefore the intervention is generalizable to other
communities and health care settings. It is uncertain, however,
what outcomes would be achieved after the implementation of
CHAP in other jurisdictions. Second, we showed that CHAP can
be successfully implemented in a large number of randomly
selected communities (i.e., 20) and in so doing can mobilize a
significant amount of community support and enthusiasm from
existing community resources and health care workers in each
community. Third, we have developed a far-reaching community-
wide intervention that, despite its complexity and overall reach,
has a relatively low cost of implementation. Fourth, the cluster
RCT design of this study meant that baseline utilization rates and
costs as potential confounding factors were controlled for in the
study. This has been a major limitation of previous community-
wide evaluations. Although a patient-level analysis with covari-
ate adjustments would have been an even stronger adjustment
[26,27], this analysis was not possible for CHAP. And finally, a
major strength of this study is the large-scale scope of the
intervention implemented and the relatively long duration of
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 3 9 – 4 5 45the intervention. With the combination of these strengths, this study
was able to show a reduction in CVD-related hospitalization costs.
Despite these strengths, the study had limitations. One is that
CHAP is a bundled intervention with many components of the
bundled intervention. As such, it is not possible to determine the
independent contribution of each component of the bundled
intervention. Another limitation is that these results apply to
medium-sized rural communities and it is uncertain whether
CHAP would be as successful in urban settings or with diverse
populations. Third, although individual patient-level analysis
would have some advantages compared with cluster community
analyses [26,27], the individual patient-level analysis was not
possible for CHAP because of the large scope of the study (i.e.,
more than 140,000 elderly residents) and the fact that the
individual patient-level consent required to access and analyze
linked patient administrative health records was not feasible or
approved for the study. And finally, CHAP was successful in
mobilizing significant community support for the intervention
communities and for the most part this volunteer assistance and
the in-kind contributions from the local lead organizations
within the CHAP communities have not been accounted for in
the analysis of implementation costs. Our sensitivity analysis
adding in various hypothetical in-kind contributions suggests
that a better accounting and analysis of these costs would likely
not result in higher overall health care and implementation costs.Conclusions
This evaluation demonstrated that this specific community-wide
CVD awareness program can be successfully implemented and
can reduce CVD-related hospitalization costs even at the level of
the community. Despite being associated with implementation
costs of approximately $71,000 per community or $20.20 per older
adult resident, the cost of CHAP was offset by slightly lower
health care costs such that overall costs were virtually identical
in both the intervention and control communities. The results
from the sensitivity analyses confirm the overall conclusion that
CHAP can be successfully implemented, can reduce CVD-related
hospitalization costs, and will not result in an overall increase in
health care costs.
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